1311P - End of life (EOL) chemotherapy (CT) in gastro-intestinal (GI) cancer patients (pts): A retrospective AGEO study

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Palliative Care
Presenter Alexandra Lapeyre-Prost
Citation Annals of Oncology (2016) 27 (6): 455-461. 10.1093/annonc/mdw384
Authors A. Lapeyre-Prost1, G. Perkins1, M. Vallee2, A. Pozet3, D. Tougeron2, M. Maillet4, C. Locher5, J. Dreanic6, J.L. Legoux7, A. Lievre8, C. Lecaille9, J. Sabate10, F. Mary11, F. Bonnetain3, H. Jaulmes-Bouillot12, B. Landi1, J. Taieb1
  • 1Gi Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 2Gastroenterology, CHU Poitiers, Jean Bernard Hôpital, 86021 - Poitiers/FR
  • 3Methodology And Quality Of Life In Oncology Unit, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 4Gastroenterology, Hôpital St. Louis, Paris/FR
  • 5Service Gastroentérologie, CH de Meaux, 77100 - Meaux/FR
  • 6Gastroenterology, Hôpital Cochin, Paris/FR
  • 7Hepato-gatroenterology And Digestive Oncology, C.H.R. Orleans - La Source, 45100 - Orleans/FR
  • 8Medical Oncology, Institut Curie, St. Cloud/FR
  • 9Hepato-gatroenterology And Digestive Oncology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux/FR
  • 10Gastroenterology, Hôpital Louis Mourier, Colombes/FR
  • 11Gi Oncology, Hôpital Avicenne, Bobigny/FR
  • 12Palliative Care Unit, Hopital European George Pompidou, Paris/FR



The use of CT during the EOL is poorly studied, with no dedicated study to GI cancer pts. Here, we report results of a retrospective study in this specific population, in the aim to analyze the factors associated to CT use within 3- and 1-month before death.


All pts that died from a GI cancer in 10 French tertiary care hospitals during 2014 were included in this retrospective cohort. Clinical (primary tumor, treatment history, performance status (PS)), demographical (age, sex, date and place of death) and biological (albumin level) data were collected and compared between pts receiving or not CT within 3- and 1-month before death. Overall survival (OS), defined as the time from diagnostic until death from any cause, was estimated using Kaplan Meier method. Univariate Cox regression's models were performed to estimate hazard ratio of all baseline variables with its 95% of confidence interval (CI).


437 pts were included in this study. All had a metastatic GI cancer (colorectal: 36.2%, pancreas: 28.4%, gastric: 10.3%, oesophageal: 9.8%, cholangiocarcinoma: 8.2%, hepatocarcinoma: 3.9%, others: 3.2%). Among them, 293 pts (67.0%) received CT within 3-months before death, and 144 (33.0%) did not, and 121 pts (27.7%) received CT within 1-month before death vs 316 (72.3%) who did not. Pts receiving CT within 3-months before death were significantly younger (median age: 65.5 vs 72.8 years, p 


In GI-cancer units, CT is given within 3- and 1- month before death, in two and one third of patients, respectively. Analysis of survivals together with a score aimed to drive treatment discontinuation decision will be presented at the meeting.

Clinical trial identification

Legal entity responsible for the study

Geraldine Perkins




All authors have declared no conflicts of interest.